A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita
A phase 3 trial of Epcoritamab, Rituximab, Lenalidomide in diffuse large b-cell lymphoma, run by Genmab, active and no longer recruiting.
Overview
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma is a phase 3 interventional study registered as NCT06508658 by Genmab, with 379 participants enrolled, started 2024-08-13 and due to reach its primary completion in 2028-03. Interventions recorded: Epcoritamab, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease
Shares Epcoritamab, Genmab, Lenalidomide, Rituximab.
- TrialA Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Shares Epcoritamab, Genmab, Diffuse large B-cell lymphoma.
- TrialA Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refr
Shares Epcoritamab, Genmab, Diffuse large B-cell lymphoma.
- TrialStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease
Shares Epcoritamab, Genmab, Lenalidomide, Rituximab.
- TrialA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl
Shares Epcoritamab, Genmab, Lenalidomide, Rituximab.
- TrialTrial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Shares Epcoritamab, Genmab, Rituximab, Diffuse large B-cell lymphoma.
- TrialStudy to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lym
Shares CAPOX (capecitabine, oxaliplatin), Rituximab, Gemcitabine, Diffuse large B-cell lymphoma.
- TrialSafety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Shares Genmab, Lenalidomide, Rituximab, Diffuse large B-cell lymphoma.